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Abstract
Purpose: CD166/ALCAM (Activated leukocyte cell adhesion molecule) as animmunoglobulin is implicated in cell migration. It is also involved in tumorigenesisof CRC (colorectal cancer) and known as a cancer stem cell marker. CD166, as amembrane protein, potentially represents either diagnostic or therapeuticcapacities for CRC. Methods: In this study, the sequence of V domain wasoptimized for expression in prokaryotic host using online tools and cloned intopET-28a plasmid. The recombinant pET28a was transformed into the E. coliBL21DE3 using heat shock method and expression of recombinant V domain wasexamined using SDS-PAGE (sodium dodecyl sulfate polyacrylamide gelelectrophoresis). Results: The results confirmed protein expression ofrecombinant 22.77 kDa V domains in bacterial expression system. Conclusion: Vdomain of the CD166 was expressed successfully in E. coli bacteria. Thisrecombinant fragment can be introduced as a suitable diagnostic and therapeuticcandidate for screening and cancer-therapy of CRC patients, respectively.
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1. IntroductionCD166/ALCAM (Activated leukocyte cell adhesionmolecule) is an immunoglobulin molecule implicated incell migration.1, 2 It is also involved in tumorigenesis ofcolorectal cancer (CRC) where functions as a cancerstem cell marker.3-5CD166, as a member of immunoglobulin superfamily,was identified by expression cloning based on its abilityto bind to the CD6, making use of COS (an acronym forCV-1 in Origin with SV40 genes) cells transfected withcDNA libraries.6, 7 CD166 is a single-pass membraneprotein with an extracellular domain consisting of500-amino acid polypeptide, and a molecular weight of105 kDa. The gene encoding CD166 is located on thelong arm of chromosome 3 (3q13.1-q13.2) and iscomposed of 16 exons, with a size over 200 kb.8 Theprotein mediates heterophilic (ALCAM-CD6) andhomophilic (ALCAM-ALCAM) cell-cell interactions.9-12ALCM consists of five extracellular domains includingtwo V-types and three C-types domains.13, 14 V domainconsists of two parts including V1 and V2 which areconsisting of 93 and 110-amino acids length,
respectively. Functional domain mapping studiesdetermined that existence of the NH2-terminal V-typedomain is required for both cell-cell (hemophilic andhetrophilic) interactions. This observation is in directionwith previous mapping studies on immunoglobulinsuperfamily cell adhesion molecules, which mostfrequently identified the N-terminal immunoglobulinsuperfamily domain as the major ligand-bindingdomain.15Several methods based on genomics and proteomicsintroduced CD166 as an oncology-related target, andidentified it as a surface antigen in CRC.8 This proteinplay a main role in CRC progression and migration.3, 16During mass lesion, cancerous cells must be attached toanother cell. Adhesion molecules can be involved indifferent types of cell adhesions including tumor cell–endothelial cell adhesion, tumor cell–matrix adhesion, ortumor cell–tumor cell adhesion playing essential roles indifferent stages of primary tumor formation ormetastasis.11CRC is the third most common type of tumors, withmore than 1.2 million new cases resulted in 600
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thousand deaths annually and ranks fourth in terms ofmortality worldwide.17 In North America and WesternEurope, CRC is the second most common cause ofcancer-related death.18, 19 According to the report ofnational Comprehensive of cancer control Ministry ofHealth and Medical Education, the range of CRCmortality in Iran is the third and fifth common cancer inIranian woman and man, respectively.20 The greatestproblem is the high capacity of CRC to form secondarytumors, particularly in the lung and liver.17, 21-23Based on functional mapping analyses, V domain inCD166 extracellular region is of great importance forboth heterophilic and hemophilic types of cell-celladhesion. It is identified as the major ligand-bindingdomain at the N-terminal immunoglobulin domain,comprising two parts, V1 and V2, consisting of 93 and110-amino acids length, respectively. Therefore, our aimin this study was to cloning and expression ofrecombinant V domain to use in diagnostic ortherapeutic applications.
2. Methods and Materials
2.1. Hosts and plasmids
E. coli BL21DE3 and TOP10 strains were used as host forexpression and cloning, respectively. The pET - 28a(+) plasmid was employed for gene expression.
2.2. Codon optimization and gene synthesisSequence encoding V domain was obtained from onlinedatabases including Swiss-port, Uniprot KB and NationalCenter for Biotechnology Information (NCBI, Gene ID:214).Codon optimization was performed based on E. colicodon usage and confirmed by genescript Company (NJ,USA). The codon-optimized construct containing theORF encoding V domain was tagged at C-terminal with6xHis-tag to facilitate its protein purification.
NcoI/BamHI and XhoI restriction sites were added to the5’ and 3’ of the sequence, respectively. The optimizedsequence was synthesized and inserted into the pBSK(+) vector (Biomatik, Canada).
2.3. Sub-cloning of V domain in pET28a
expression plasmidTo amplify V-domain, E. coli TOP10 was transformed bypBSK (+) vector. After plasmid extraction (Fermentas,Lithuania), a double digestion was done with NcoI and
XhoI (Fermentas, Lithuania). The expression vectorpET28a was also digested with same enzymes. Doubledigestion was carried out at 37 ºC. Digested fragmentswere analyzed by agarose gel electrophoresis andpET28a expression vector and V-Domain fragmentswere purified (Fermentas, Lithuania). Finally, V domain
sequence was ligated to the pET28a using T4 DNA ligase(Fermentas, Lithuania).
2.4. Transformation of Recombinant Vector
(pet-28a- V domain)In this study, competent E. coli BL21 (DE3) host cellswere prepared according to Calcium Chloride method.24The accuracy of transformation was verified by doubledigestion of plasmid with NcoI and XhoI enzymes.
2.5. Expression20 μL of an overnight pre-cultured transformedbacterial cells was inoculated to 2 ml fresh LB mediumcontaining kanamycin (100 μg.mL-1) and incubated in ashaker incubator for 2 h at 150 rpm (37 ºC) untilreaching the optimized optical density (0.8). 20 μL IPTG(100 μg.mL-1) was added to the medium to induceprotein expression and incubation was performed in theshakers incubator for 6 h at 150 rpm and 37 ºC. Themixture was centrifuged for 5 min at 5000 rpm and 4 °C.Supernatant was discarded and 60 μL Urea (8 M) wasadded to the precipitate.
2.6. Analysis of V domain expressionExpression of the V-domain was evaluated by SDS-PAGE.To run the samples, the mixture (precipitated sampleand Urea) was dissolved in 1x SDS-PAGE sample buffer.Protein molecular weight marker and the preparedsample were heated at 95ºC for 5 min. Afterward,marker and sample were loaded on the 12% SDS-PAGEgel and run with the constant voltage of 100 V. The gelwas stained with Coomasie brilliant blue R-250 for 2 hand washed with water followed by destaining for 2 h
3. ResultsThe synthetic V-domain gene was assembled based onthe E. coli codon usage. The reference sequence of thegene employs tandem rare codons which can decreasethe productivity of translation or even disengage thetranslational machinery. The codon usage bias of thegene was changed in E.coli by upgrading the CodonAdaptation Index (CAI) and Frequency of OptimalCodons (FOP) from 0.62 to 0.88 and 44 to 68,respectively. CAI of > 0.8 is considered as good, in termsof high gene expression level. Moreover, 100 is set forthe codon with the highest usage frequency for a givenamino acid in the desired expression organism (Figure1).The GC content was changed from 42.17% to 47.69% inoptimized sequence. Between 30-70% is ideal percentrange of GC content (Figure 2). Nucleotide sequence oforiginal and optimized sequences were compared forPeer to Peer (Figure 3).
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Figure: 1. Codon usage bias in E. coli: (A) Codon Adaptation Index (CAI); Right: before optimization, Left: after optimization;(B) Frequency of Optimal Codons (FOC); Right: before optimization, Left: after optimization.
Figure: 2. GC Content adjustment; Right: before optimization, Left: After optimization.
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Figure: 3. DNA Alignment; Comparing nucleotide for peer to peer in the primary and optimized sequences.
The synthetic gene was constructed from 662 bp locatedbetween NcoI and XhoI restriction sites and coloned intopBSK (+) vector (Figure 4).
Figure: 4. Schematic figure of construct map pBSK(+)simple-Amp-V dmain
The V-domain gene was amplified by transformed pBSK(+) vector into E. coli top10. It was digested andsubcloned into pET-28a expression vector successfully(Figure 5).
Figure: 5. Double digestion of pBSK (+) vector (with theNcoI and the XhoI);M, GeneRuler™ 1 kb ladder (Fermentas,Lithuania) and Lane 1, 2 and 3 Double digested plasmid.
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E. coli BL21 (DE3) was transformed by recombinantconstruct. The LB agar was supplemented withkanamycin (100 μg.mL-1) as antibiotic to assurance thescreening process. Transformed colonies were observedafter 18 to 20 h incubation at 37 ºC. After extraction ofthe transformed plasmid, double digestion verified theaccuracy of transformation (Figure 6).
Figure: 6. (A) Extraction of transformed plasmid (pET-28aRecombinant Vector); M, GeneRuler™ 1 kb ladder; Lane 1, 2and 3: Extraction of transformed plasmid; (B) The doubledigestion of pET-28a recombinant vector (with the NcoIand the XhoI); M, GeneRuler™ 1 kb ladder; Lane 1, doubledigestion.
Figure: 7. Expression analysis of recombinant V Domainproduced in E. coli BL21 (DE3) by SDS-PAGE; line M,protein marker (CMG, Iran); line1, 2 and 3: Induction of E.coli BL21 (DE3) with IPTG; lane 4: Non- induced E. coliBL21 (DE3).
Recombinant clones were selected, grown in LB Mediaand induced with IPTG. The expression of recombinant Vdomain was examined by SDS-PAGE. Since the weight ofthe recombinant protein together with 6x His-tag isapproximately 23 kDa, 12% SDS-PAGE gel was used(Figure 7).
4. DiscussionCD166, as an immunoglobulin molecule, is involved intumorigenesis of CRC.2, 3, 25-28 The protein mediatesheterophilic and homophilic cell-cell interactions andimplicated in cell migration.1, 9 As well as other specificmembrane proteins, CD166 can be applied potentially asa suitable target for cancer therapy.16 CD166 as a cellsurface antigen, can be used for several purposes such aspredicting the response to treatment and sorting cancerstem cells.29, 30The specific expression pattern of CD166 suggests thismarker as an effective therapeutic target for CRC. CD166is significantly overexpressed in CRC while normallyexpressed in intestinal cells surface.31 It is also known asa cancer stem cell marker protein and believed to haveunique ability to develop self-renewal of cancer cellsleading to form the source of many human tumors.32Common methods of chemotherapy target differentiatedor differentiating cells that form the bulk of the tumor.But it should be noted that these cells are only the size ofthe tumor and are not able to produce new cells andhave no role in disease progression and tumor growth,while the population of cancer cells that cause cancerand tumor growth remains intact and out of sight,thereby causing recurrence of the disease. So given thatCD166 is introduced as a surface cell stem marker forCRC, it can be an appropriate candidate to be focused fordiagnostic and therapeutic applications.33, 34It is also one of the main components for CRC metastasisto the liver and lung tissues.15 Cancer cells use stickymolecules to be connected to each other duringformation of mass lesions. Adhesion molecules areinvolved in interaction with the extracellular matrix,cell-cell adhesion, local invasion, dissemination by intra-vascularization, as well as formation of metastases viathe blood or lymphatic system in distant organs.Therefore, a set of the functions of a adhesion moleculesis a strategy with impact for intervention in theprogression of cancer.7, 35Based on functional mapping studies, the presence of Vzone is essential for both CD166 heterophilic andhemophilic reactions. This observation was in line withmapping studies of immunoglobulin superfamily celladhesion molecules, which most frequently identifiedthe V domain as the major ligand-binding domain. Giventhe importance of V domain in promoting CD166reactions and its presence in extracellular region,
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cloning and expression of V domain seems necessary topresent it as a platform for diagnostic and therapeuticreasons.Cancer stem cell markers are used for different purposessuch as early diagnosis screening, determining the originof cancer, either prognosis or diagnosis of tumorinvasion, analyzing the effectiveness of the treatment,and finding a suitable treatment and diagnosis of cancerrecurrence after surgery and chemotherapy. In thisstudy, we aimed to produce the V domain in suitableprokaryotic host to provide necessary conditions for itspurification and isolation.  This recombinant proteincan be used in laboratory for cellular immunityinduction and confirmation of its immunogenicity undernatural conditions. Furthermore, it can be used toimprove diagnostic procedures (diagnostic kits) ortherapies (vaccines) for colorectal cancer.According to precious specificity and ability of theimmune system, vaccination is in theory the mostaccurate and strong approach for controlling cancer.36The long-standing target in cancer immunology andmedical oncology has been special activation of theimmune system to control cancer growth in vivo. Theuse of antigen-specific vaccination is the eventuality ofmonitoring special vaccine-induced immuneresponses.37In addition, given that post-translational modificationsof glycosylation does not affect the binding properties ofhemophilic CD16615 (Figure 8); therefore, the choice of
E. coli as host for expression can be an appropriateoption for reducing costs and increasing the expression.
5. ConclusionCD 166, as a stem cell marker, plays important roles intumor progression and invasion of colorectal cancer.Since the V domain of CD166 is located on theextracellular region playing very important role ininteractions, and enjoy a proper size, it can be a goodchoice as a potential target for the treatment anddiagnosis of colorectal cancer. The result of this studydemonstrated high level of V domain expression in E.
coli system using pET28a expression vector.
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